Shellcure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-05-2024
- Paid Up Capital ₹ 0.10 M
as on 15-05-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
- Revenue -6.94%
(FY 2020)
- Profit 72.11%
(FY 2020)
- Ebitda -101.44%
(FY 2020)
- Net Worth -3.42%
(FY 2020)
- Total Assets -20.52%
(FY 2020)
About Shellcure Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sushant Navandhar, Dhairyashil Shinde, and Vikram Shinde serve as directors at the Company.
- CIN/LLPIN
U85100PN2015PTC153620
- Company No.
153620
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2015
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Shellcure Pharmaceuticals Private Limited offer?
Shellcure Pharmaceuticals Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Pharmaceutical Chemists.
Who are the key members and board of directors at Shellcure Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushant Navandhar  | Additional Director | 30-Jun-2020 | Current |
| Dhairyashil Shinde | Director | 06-Jan-2015 | Current |
| Vikram Shinde | Director | 06-Jan-2015 | Current |
Financial Performance of Shellcure Pharmaceuticals.
Shellcure Pharmaceuticals Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 6.94% decrease. The company also saw a substantial improvement in profitability, with a 72.11% increase in profit. The company's net worth dipped by a decrease of 3.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shellcure Pharmaceuticals?
In 2016, Shellcure Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Phyllus Pharmaceuticals Private LimitedActive 3 years 3 monthsDhairyashil Shinde is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shellcure Pharmaceuticals?
Unlock and access historical data on people associated with Shellcure Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shellcure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shellcure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
